Study Design. The Medline and Embase databases containing randomized controlled trials of injection therapy published to 1998 were systematically reviewed.
The burden of chronic low back pain on society is enormous in terms of both patient suffering and cost (Quebec Task Force on Spinal Disorders, 1987). Numerous treatments have been advocated, but not many have proved to be effective (Bell, 1984; Deyo, 1984) . Injection with anesthetics, steroids, or both is one of the treatment methods used to treat patients with chronic low back pain, which needs evaluation with respect to the effectiveness for short-and long-term pain relief.
Injection therapy is applied at different locations. Injections into facet joints have been presented as treatment and also as a diagnostic test for the lumbar facetjoint syndrome. There are no objective criteria for this syndrome. The clinical diagnosis is based on the presence of localized lumbar pain, which may radiate to the posterior aspect of the thigh and be relieved by an injection of corticosteroids and local anesthetic (Mooney(b), 1987; Mooney(a); Robertson, 1976) .
Injections can be given intra-or periarticularly. Epidural anesthesia involves injection of a solution of local anesthetic into the epidural space. The anesthetic acts in two places. It diffuses across the dura into the subarachnoid space, where it acts on nerve roots and the spinal cord. The drug also diffuses into the paravertebral area through the intervertebral foramens, producing, in essence, multiple paravertebral nerve blocks. The subarachnoid space is the more important site of action (Ritchie, 1990) .
Local injection therapy is a badly defined term. Injections can be administered for several syndromes. In the reviewed studies, injections were used at many locations. Sometimes the anesthetic was injected into the iliolumbar ligaments, but injections into tender points, trigger points, or acupuncture points and intradiscal injections also are mentioned in the reports. Sometimes it is not even clear into which tissue the anesthetic has been injected.
Many controversies exist regarding the effectiveness of injection therapy. It is not clear why an injection with a short-acting anesthetic would provide prolonged pain relief. Furthermore, randomized controlled studies on the effectiveness of injection therapy have yielded controversial results. Evidence for both short-and long-term effectiveness is lacking.
Recent reviews have shown contradictory results, although there has been considerable overlap between the trials included in these reviews (Koes et al, 1995; Watts et al, 1995) . Koes et al reviewed 12 randomized clinical trials on the efficacy of epidural steroid injections for low back pain and sciatica. One half of the trials reported positive outcomes from epidural steroid injections, and the other half reported negative outcomes. Critical assessment of the methods used in these trials showed flaws in the design for most of the studies, although there appeared to be no relation between the methodologic quality of the trials and the reported outcomes. Koes et al concluded that the efficacy of epidural injections has not yet been established.
Watts et al performed a meta-analysis of 11 placebocontrolled trials on the efficacy of epidural steroid injections in the treatment of sciatica, nine of which also were considered by Koes. The methodologic quality of the trials was considered generally to be good for the five studies that scored the maximum number of points. Improvement of at least 75% or reduction in pain was considered to be a clinically useful response. With respect to short-term pain relief (1 to 60 days), the pooled odds ratio (OR), based on 10 trials, was 2.61 (95% confidence interval [CI] ϭ 1.80 -3.77), whereas for long-term pain relief (12 weeks to 1 year), the pooled odds ratio, based on 5 trials, was 1.87 (95% CI ϭ 1.31-2.68). Watts et al concluded that epidural steroid injections are effective in the management of patients with sciatica.
The current authors decided to perform another systematic review of randomized clinical trials on the efficacy of injection therapy in patients with low back pain. This review differed from the previous reviews because 1) it did not restrict itself to epidural steroid injections, but also considered epidural injections with anesthetics and other injection sites such as facet joints and local sites; and 2) it was restricted to randomized clinical trials, which included patients with low back pain persisting longer than 1 month. This inclusion criterion was used to reduce the chance of spontaneous recovery.
There is an 80% to 90% probability that patients with low back pain will recover spontaneously within 3 months, with the chance of recovery diminishing as time passes (Garvey et al, 1989) . In a clinical trial, a high spontaneous success rate in the control group is "noise" that may obscure the efficacy of active treatment, making the trial inefficient. This can be illustrated by an example. Supposing that active therapy will cure 50% of the patients who will not recover spontaneously, if the spontaneous recovery rate is 30% in the control group, then 65% (30% ϩ [0.5 ϫ 70%]) of the patients in the experimental group will recover, yielding a difference of 35%. If the spontaneous recovery rate in the control group is 10%, then 55% (10% ϩ [(0.5 ϫ 90%]) of the patients in the experimental group will recover, yielding a difference of 45%. Therefore, it is easier to show an effect by keeping spontaneous recovery rates low (Knipschild, 1991) . One way to achieve low recovery rates might be to restrict the study population to patients with low back pain persisting longer than 1 month. Experience teaches that the longer the duration of low back pain in the control group, the smaller the proportion of patients with a natural tendency to improve.
Methods

Inclusion Criteria for Studies
Types of Studies. To be included in this review, studies had to meet three criteria. First, the study design had to be a randomized clinical trial. Second, the treatment had to include injection therapy for pain relief, although additional treatments were allowed. Third, the patients had to have benign chronic low back pain with symptoms persisting longer than 1 month.
Types of Participants. The study population, as defined by the inclusion and exclusion criteria for this review, consisted of patients with subacute and chronic low back pain (i.e., lasting longer than 1 month).
Types of Interventions. Injection therapy was studied at three injection sites: facet joints, epidural sites, and local sites.
Types of Outcome Measures. The percentage of patients with pain relief was considered to be the most important outcome measure. Pain is evaluated on both a short-term (Ͻ6 weeks) and long-term (Ͼ6 weeks) basis. Other outcome measures other than pain used in the trials also were listed.
Search Strategy for Identifying Studies.
Medline and Embase searches of papers published over the period 1966 -1998 were conducted. The keywords used were low back pain, back, neck, injections, chemonucleolysis, rhizotomy, facet denervation, thermolesion, trial, random, controlled, and review. Citation tracking was performed until no new studies were found. Abstracts and unpublished studies were not included. English, French, German, Dutch, and Nordic languages were considered eligible for retrieval purposes.
Review Methods.
Study Selection. Studies were selected if they met the three inclusion criteria.
Data Extraction. A standardized form was used to extract the relevant data on the methods used, participants, interventions, outcome measures used and timing of outcome measurement, reported side effects, and the main results.
Data Analysis. The proportion of patients with pain relief was used as the primary outcome measure in this review. Raw data on the number of patients with pain relief and the total number of patients in each treatment group were entered into Review Manager. The included trials were subdivided according to the injection site studied (facet-joint vs epidural vs local injection), the type of trial (explanatory vs pragmatic), and timing of the outcome measurement (within 6 weeks of intervention vs 6 weeks after intervention). A trial was designated as explanatory if the control group had a placebo injection, and as pragmatic if the control groups had another type of active injection. Within the resulting 12 (3 ϫ 2 ϫ 2) subcategories of studies, the overall relative risks and corresponding 95% confidence intervals were estimated, using a random effects model designed by DerSimonian and Laird. In the case of pragmatic studies, the results were not pooled.
Methodologic Quality. The methodologic quality of the studies under review was scored by using a criteria list (ter Riet et al, 1990). The following table specifies the items evaluated:
• A selection and restriction (4 points) • B treatment allocation (15 The criteria were based on generally accepted principles of intervention research (Meinert, 1986; Pocock, 1991) . Studies could earn points for each criterion met. The maximum score was 100 points. The quality of the study methods was scored independently by two reviewers (R.dB., H.dV.). In a meeting, the reviewers reached consensus on the small number of criteria (5%) about which they disagreed.
Items Used to Assess Methodologic Quality and Justification of Weights.
Internal Validity. More than half of the points could be earned with items on the criteria list that were pivotal for ensuring validity.
Treatment Allocation (B).
Randomization is essental to ensure balance for any unknown or known prognostic factors so that unbiased comparisons between intervention groups can be made. Information on the randomization procedure had to be given in sufficient detail to enable the reviewers to judge whether the procedure was foolproof in concealing the assigned treatment from the referring clinicians.
Prognostic Comparability (D).
The maximal score was assigned to publications wherein the distribution of seven baseline characteristics (age, gender, duration of symptoms, baseline scores for outcome measures, concomitant medication, previous operations, and effectiveness of prognostic blocking) was similar and clearly presented for intervention groups. The number of points on this item was determined by the number of characteristics for which the intervention groups were comparable multiplied by 10/7.
Blinding of the Patient, Therapist, and Observer to Treatment Allocation (I,J,K). Half of the maximal score (6 points) could be earned by attempts to blind the patient, therapist, and/or observer, for example, by using a placebo injection with the control group, or by letting an observer, who was unaware of the treatment allocation, assess clinical outcome. The more subjective the measurement of clinical outcome is, the more important masking techniques become. All 12 points were assigned when the authors had checked whether the blinding had succeeded.
Number of Dropouts and Losses to Follow-Up Assessment (E,F).
Information on the flow of participants had to include the number of participants eligible, randomized, treated, and completing or failing to complete the trial by intervention group. "Dropouts" were patients who were randomized but did not complete the intervention, such as noncompliant patients and those experiencing serious adverse effects. "Losses to follow-up assessment" referred to patients who finished treatment but did not return for all the measurements of clinical outcome. Trials scored well if the numbers of dropouts and losses to follow-up assessment were rather small (dropouts less than 5%, losses to follow-up assessment less than 10%) or the reasons were not related to clinical outcome. In these situations, the resulting bias was regarded as small and as not seriously affecting the results of the trial.
Extra Treatments (H).
Cointerventions had to be reported, and extra treatments with a potential beneficial effect on clinical outcome had to be comparable in both intervention groups.
Relevance. Items such as selection and restriction (A), intervention (G), outcome measures (L), timing of outcome measurements (M), and side effects (N) refer to relevance of the trial to clinical practice.
Description of Inclusion and Exclusion Criteria (A).
This item was considered to be important because it informs the reader about the type of patients to whom the study results apply and the homogeneity of the study population.
Intervention (G)
. Interventions had to be described in detail in terms of dose, technique, route, and frequency of administration.
Outcome Measurements (L).
Measures for assessing and recording a patient's progress had to be defined clearly. The score on the "outcome measures" item depended on the number of relevant measures (pain, global improvement, functional physical status, medical consumption, functional status). For example, a study having six outcome measurements, of which only one was considered relevant, the score was calculated as 1/6 ϫ 5 ϭ 0.8 points.
Timing of Outcome Measurements (M).
The timing of outcome measurements had to be stated explicitly so short-term and long-term effects could be distinguished.
Side Effects (N).
Accurate reporting of side effects according to treatment group was considered to be necessary for evaluating the safety of the intervention(s) under study.
Statistical Approaches. Although many statistical aspects could be considered, the checklist for the current study focused on study size (C) as well as analysis and presentation of data (O).
Study size (C).
A maximal score was allocated in cases of adequate sample size. Trials with insufficient sample size may cause potentially useful new therapies to be ignored (Type 2 error or ␤ error). The power of the study (i.e., the probability of detecting a postulated level of effect) is too low. In these situations, the lack of statistical significance does not allow the conclusion that the intervention under study was not effective.
Analysis and interpretation of data (O).
With respect to the presentation of data, a trial could score well if the data were presented in a way that allowed a number of simple effect measures (e.g., percentage of patients with pain improvement) to be compared by the reviewers and statistical analyses to be checked. Furthermore, the scoring list addressed the question whether the primary analysis was performed according to the intention-to-treat principle, meaning that the analysis included all the participants and their follow-up results in the intervention groups to which they were assigned initially. Such analysis was preferred because it does not violate the comparability of baseline characteristics and relates to actual clinical practice.
Results
The search strategy yielded 40 papers. 1,3-9,11,12,14 -19, 22-27,29,32,33,35,37,38,41-50,52,53 After detailed reading, 19 studies were excluded: Six of these studies appeared to be nonrandomized. 12, 14, [43] [44] [45] 52 In one study, an anesthetic agent was injected into the wound during surgery, 29 and in seven studies, either patients with acute problems (Ͻ1 month) were included 11, 17, 35, 48, 50 or the duration of the reported problems was not described. 19, 53 Five studies 24, 25, 32, 37, 38 fell outside the domain of this review. The two reports by Lillius et al 22, 23 described the same study, so both were used to assess the methodologic quality of the study. The report by Matthews et al 27 described several trials, one concerning local injection and another about one epidural injection.
Eventually, 21 papers describing 21 trials were included for review. The characteristics of the included studies are described in Table 1 . The excluded studies and the reasons for their exclusion are described in Table 2 .
Methodologic Quality of the Included Studies
The methodologic quality of the studies varied from 23 to 83 out of 100 possible points (Table 3) . Most of the studies gave an adequate description of the intervention, the timing of the outcome, and the side effects. However, on all other items most of the studies received less than 50% of the maximum score. Initially, there was a 5% rate of disagreement between the two independent reviewers, mainly caused by reading and/or interpretation errors. In a consensus meeting, the differences were resolved. The scores on individual items are tabulated in Tables 4 and 5 .
Study Population
The study population, as defined by the inclusion and exclusion criteria, consisted of patients with chronic low back pain. Additional characteristics differed per study, especially with respect to duration of reported problems, radicular symptoms, and operation. Epidural injections were used mainly for patients with sciatica. Exceptions were the studies of Glynn et al (1988) and Serrao et al (1992) . Facetal joint injections were used with patients suspected of having the facet-joint syndrome. Carette et al (1991) tried to specify the diagnosis by including only patients who responded to injection of lidocaine into the facetal joint and showed pain relief of at least 50%. The trials on the effect of local injections included patients with iliac crest syndrome (Collée et al, 1991) ,myofascial syndrome (Hameroff et al, 1981) , nonspecified low back pain (Garvey et al, 1989; Mathews et al, 1987; Ongley et al, 1987) , or mechanical low back pain (Serrao et al, 1992) .
Interventions
Eleven studies were of an explanatory nature, comparing an experimental therapy with a placebo injection (e.g., saline or procaine). The remainder of the studies compared two active agents and are referred to as pragmatic studies. A diversity of drugs was used in the reviewed studies. These drugs can be divided roughly into anesthetics, steroids, benzodiazepines (midazolam), opioids, and sclerosants. Apart from the medication used, the volume, the dose, and site of injection also varied. Moreover, there were differences between the studies with respect to the injection techniques. Some of the epidural injections were caudal (i.e., through the sacral hiatus (Bush and Hillier, 1991) .
Effect Measurements
In all the studies, pain was considered to be the most important outcome measure. Pain usually was measured on a visual analogue scale or an ordinal scale, but often was dichotomized into satisfactory pain relief or no pain relief for the final outcome. Many studies assessed only 
Effectiveness of Injection Therapy
With respect to facet-joint injections, Carette et al (a) (1991) reported that they did not find significant differences in proportions of pain improvement between cor- Epidural injections:
1. 2 mL (80 mg) methylprednisolone ϩ 40 mL of procaine 0.5%
(n ϭ 24).
2. 42 mL of procaine 0.5% (n ϭ 24).
Timing: 1 week after injection.
Outcome measures:
change in pain.
Side effects: mild headache and dizziness (n ϭ 10). 2. 20 mL bupivacaine 0.25%
followed by 100 mL saline (n ϭ 19). Frequency: up to three injections at weekly intervals.
Timing: not mentioned. Epidural injections:
1. 25 mL (80 mg) triamnicolone acetonide ϩ 0.5% procaine hydrochloride (n ϭ 12).
25 mL normal saline (n ϭ 11).
Two caudal injections, the first after admission to the trial and a second after 2 weeks.
Timing: at 4 weeks and at 1 year.
1. effect on lifestyle. data not shown). Timing: at 2 weeks.
pain on a scale of 1-10 improved vs not improved.
Side effects: increased pain:
injection (n ϭ 1), dryneedle stick (n ϭ 2).
Fever, chills, and systemic upset: dry needlestick (n ϭ 1).
Score: 34.8%.
A (Table continues) ticosteroid and saline injections 1 and 3 months after injection. The short-term risk ratio (RR) was 0.89 (95% CI ϭ 0.65-1.21) and long-term RR was 0.90 (95% CI ϭ 0.69 -1.17). These numbers indicate that there was no significant difference between the groups. At 6 months, the percentage of patients with marked or very marked improvement was significantly higher in the group treated with methylprednisolone (46% vs 15%; P ϭ 0.002). Despite this latter finding, it was concluded that the efficacy of facet-joint injections is small because 11 of Epidural injections: (n ϭ 20)
1. 10 mL bupivacaine 0.5% ϩ morphine (5 mg). Outcome measures:
1. pain (recovered vs not recovered).
ranges of movement
(no significant differences; data not reported).
SLR (no significant
differences; data not reported).
neurologic examination
Side effects: none. Score:
66.8%. Timing: at 6 months after injection.
1. functional impairment (by questionnaires) (not reported).
psychological dysfunction (not reported).
3. pain.
Side effects: marked ventilatory depression.
Unethical to continue the study. Score: 47.8%. B (Table continues) the 22 patients in the steroid group who reported substantial improvement at 6 months after injection reported no benefit at earlier evaluations. No pharmacologic or biologic explanation can be offered for these results. Moreover, cointerventions were more frequent in the steroid group. The study of Lilius et al (1989 Lilius et al ( , 1990 reported that mean scores for pain relief with methylprednisolone, bupivacaine, or both were not superior to those for placebo injections. The study by Lilius did not report proportions of patients with pain relief. The pragmatic trial of Marks et al (1992) found that facet-joint injections with methylprednisolone and lignocaine produced slightly better results than the facet nerve blocks. The response usually was short-lived: 3 months after therapy, only two patients continued to report complete pain relief. The short-term RR was 0.81 (95% CI ϭ 0.62-1.06), and the long-term RR was 0.91 (95% CI ϭ 0.74 -1.12). These numbers indicate that no significant difference was found between the groups. The subcategories of studies on facet-joint injections (explanatory and pragmatic) contained only one study, so pooling of the data was not possible. With respect to epidural injections, the studies by Cuckler et al (1985) and Beliveau (1971) were consid- Epidural injections:
1. 14 mL lignocaine 2%, methylprednisolone acetate 80 mg in 2 mL aqueous suspension and 4 mL normal saline (n ϭ 15).
2. 14 mL lignocaine 2% with 6 mL normal saline (n ϭ 15).
Timing: at 1 month
Outcome measure (sum of changes in four categories):
1. pain score.
2. work status (not poolable).
analgesic consumption
(not poolable). Intradiscal injections:
1. methylprednisolone 80 mg/mL (n ϭ 14).
2. bupivacaine 0.5% 1.5 mL (n ϭ 11).
Timing: 10-14 days after discography.
1. Oswestry Pain Questionnaire.
2. pain VAS. ered to be explanatory studies. These studies used procaine rather than procaine combined with methylprednisolone in the control groups. Whether injection with procaine may be considered a placebo injection is not clear. No available studies compare a lignocaine or procaine injection with a saline injection. There might be some specific effects from an injection with a local anesthetic including "interruption of sustained neural activity that produced and perpetuated the pain, relaxation of paraspinal muscle spasm, and resolution of accompanying reflex sympathetic dystrophy." However, from a pharmacologic point of view, procaine is unlikely to result in lasting pain relief because it has a very short duration of action (20 to 45 minutes) (Ritchie, 1990) . For this reason, treatment with procaine was considered to be placebo treatment. Altogether, there were four explanatory trials on the short-term efficacy of epidural injections (Beliveau, 1971; Bush and Hillier, 1991; Carette et al (b), 1997; Cuckler et al, 1985) . All the trials reported that pain relief within 6 months after intervention occurred more often in the experimental group, but the differences in proportions of patients with improvement were not statistically significant (alpha ϭ 0.05; pooled RR ϭ 0.93; 95% CI ϭ 0.79 -1.09). Three of these trials (Bush and Hillier, 1991; Carette et al (b), 1997; Cuckler et al, 1985) reported on pain relief more than 6 weeks after intervention (pooled RR ϭ 0.92; 95% CI ϭ 0.76 -1.11). These numbers indicate that there was no significant difference between the groups.
Six pragmatic trials reported on short-term pain relief (Breivik et al, 1976; Dallas et al, 1987; Glynn et al, 1988; Mathews et al, 1987; Rocco et al, 1989; Rogers, 1992) . Four of these six trials showed a nonsignificant positive effect. One study showed a significant difference between morphine-steroid and saline-steroid injections regarding pain relief within 6 weeks (Dallas et al, 1987) . However, only 65% of the patients reported pain relief that lasted only 1 day to 6 weeks. Morphine was found to cause adverse side effects frequently. None of the two pragmatic trials reporting on long-term pain relief by epidural injection found significant differences between treatment groups (Mathews et al, 1987; Serrao et al, 1992) .
With respect to local injections, five explanatory trials were identified (Collée et al, 1991; Garvey et al, 1989; Hameroff et al, 1981; Ongley et al, 1987; Sonne et al, 1985) . Four of these studies indicated that injection therapy was more effective than placebo injection, irrespective of the medication used (Collée et al, 1911 ; Hameroff Sonne et al, 1985) . One study showed the opposite effect (Garvey et al, 1989 ): A single dry needlestick acupuncture appeared to be more effective than injections with steroid, lidocaine, or both, although the difference in effect was not statistically significant. After the results from three explanatory trials that presented raw data on the proportions of patients with short-term pain relief (Collée et al, 1991; Garvey et al, 1989; Sonne et al, 1985) were pooled, the RR was 0.80 (95% CI ϭ 0.40 -1.59). These numbers indicate that there was no significant difference between the groups. The only explanatory trial on long-term pain relief, that of Ongley et al (1987) , reported a significant difference in proportions of patients with pain relief between the two groups (88% vs 39%; RR ϭ 0.79; 95% CI ϭ 0.65-0.96), indicating that local injection combined with forceful manipulation was superior to placebo injection combined with light manipulation.
There were two pragmatic trials on local injections (Mathews et al, 1987; Simmons et al, 1992) . Neither of these trials showed significant differences between treatment groups.
Side Effects
In general, few side effects were reported by the studies on epidural and local injection therapy with anesthetics or steroids. The use of morphine often was associated with side effects such as pruritus, nausea, and vomiting.
Discussion
This systematic review of 21 clinical trials on the effectiveness of injection therapy in patients with chronic low back pain shows that very little useful information can be derived from these studies. Injections into the facet joints do not seem to be effective, but with only one explanatory trial (a comparison with saline) of good quality to be found in this field (Carette et al (a), 1991), conclusions must be drawn with prudence. No conclusion can be stated regarding the effect of epidural injection therapy. Four explanatory trials showed nonsignificant positive results from epidural injections, but the pooled odds ratio was not significantly different from 1. The short-term RR (based on four trials) was 0.93 (95% CI ϭ 0.79 -1.09). The long-term RR (based on three trials) was 0.92 (95% CI ϭ 0.76 -1.11).
These numbers indicate that there was no significant difference between the groups. With respect to local injections at trigger points or ligaments, four of five explanatory trials consistently indicated more pain relief at these locations than that offered by placebo injections. The pooled short-term RR (based on three trials) was 0.80 (95% CI ϭ 0.40 -1.59). These numbers indicate that there was no significant difference between the groups. The results on long-term pain relief were reported by only one trial (Ongley et al, 1987) , which found a statistically significant difference between treatment groups (RR ϭ 0.79 (95% CI ϭ 0.65-0.96). These numbers indicate that trigger-point injections are better than placebo injection in terms of long-term pain relief.
Of the 21 clinical trials under review, 11 were explanatory. That is, they compared injection with active medication versus saline or procaine injection, which in the authors' opinion is the only way to address the question whether injection therapy is effective. The other studies compared two or more potentially active techniques to find out which was most effective. Most comparisons between different anesthetic agents did not show that one agent was significantly better than the other.
A question that remained unanswered during the review of selected trials on injection therapy is why some investigators used short-acting anesthetics such as lignocaine (Collée et al, 1991; Mathews et al, 1987) or procaine (Beliveau, 1971; Cuckler et al, 1885) instead of bupivacaine or etidocaine. The authors themselves gave no explanation for their choice.
Another issue seldom addressed involved the volume of fluid used, which, especially with epidural injections, might be important according to theoretical considerations. Volumes per epidural injection varied from 7 mL (Cuckler et al, 1985 ) to 42 mL (Beliveau, 1971). Evans (1930) , for example, who wrote about epidural injections in the treatment of sciatica, expressed the opinion that the effect was based on the physical displacement of the neural elements caused by a large volume of injected fluid. This could lead to stretching and lysis of neural adhesions, and even to anesthesia from compressive effects. Evans (1930) observed no difference between anesthetic or physiologic saline solution in effects obtained.
Whether this opinion is true or not, such considerations affect the design of the trial. If researchers believe in physical effects of injected fluid, the contrast between intervention groups should refer to the volumes injected. If they believe in pharmacologic effects, the type and duration of action from medication become more relevant.
The question whether injection therapy results in long-term pain relief was addressed by only a few studies. This is striking because the duration of pain relief is a clinically relevant issue that plays a role in the decision to use injection therapy in patients with chronic pain.
Considering methodologic quality according to standards currently recommended for conducting clinical trials, most of the reviewed studies scored low. Therefore, the opportunity for bias was high.
The current authors can think of four important reasons why potential beneficial effects from injection therapy could have been missed. First, in most of the studies, the sample sizes were too small. Therefore, the power (i.e., the probability to detect small but clinically relevant differences in effect) was too low. Despite the pooled analysis, the lack of power might still be a serious problem because the studies were divided according to location of injection (facet joint vs epidural vs local), type of comparison (explanatory vs pragmatic), and duration of pain relief (Ͻ6 weeks vs Ͼ6 weeks). From the resulting 12 subcategories of studies, data from a maximum of 4 studies could be pooled.
Second, recovery rates in the groups treated by saline injections turned out to be substantial (mostly varying from 20% to 33%). There are two possible explanations for this observation: 1) Injection with saline might be effective either by a physical effect as proposed by Evans (1930) or by a placebo effect, or 2) the high recovery rates in the placebo group may reflect the natural course of low back pain, and thus, restriction of the review to trials including patients with low back pain persisting for more than 1 month did not result in the selection of study populations with low recovery rates.
Third, low back pain is not a well-specified disease entity. Many types of patients with different causes of low back pain were included. Investigators who seriously tried to select a homogeneous population had to cope with the problem that diagnosing the origin of low back pain is notoriously difficult. Such (almost inevitable) diagnostic inaccuracy results in heterogeneity of the study population, causing the effects of an intervention that might be beneficial for some types of back pain to be diluted by the inclusion of patients who cannot benefit from the intervention. For example, in an evaluation of the effect from facetal joint injections, the efficacy of the treatment method might be diluted by the inclusion of patients without a facet-joint syndrome.
Fourth, most studies measured pain on a visual analog or ordinal scale, but used dichotomized results (im-proved vs not improved) in the analysis. In this way, information is unnecessarily lost, and subtle improvements that are clinically relevant could be missed.
Conclusions
Implications for Practice
Facet-joint, epidural, and local injection therapies have not yet been proved effective, nor have they been proved ineffective. Because of the tendency toward positive results favoring injection therapy, and because of the minor side effects reported in the reviewed studies, there currently is no justification for abandoning injection therapy for patients with low back pain. However, because statistically significant results are lacking and welldesigned trials are scarce, a solid foundation for the effectiveness of injection therapy also is lacking.
Implications for Research
Facet-Joint Injections. A solid foundation for the effectiveness of injection therapy is lacking. Only one welldesigned study on facet-joint injection therapy was found, and its results were statistically nonsignificant.
Epidural Injections. There is insufficient evidence for the effectiveness of epidural injection therapy. There was a tendency towards results favoring active injections over placebo injections, but the pooled relative risks were statistically nonsignificant and there was only one well designed study.
Local Injections. There is insufficient evidence to prove the effectiveness of local injection therapy. Two of three studies on the short-term effect yielded results favoring local injections over placebo injections, but the pooled relative risk was statistically nonsignificant. Only one well-designed study on the long-term effect was found that had statistically significant results favoring local injection over placebo injection.
Evidence on the effectiveness of injection therapy is still lacking. Therefore, large, well-designed trials on the effects of facet-joint, epidural, and local injection therapies are needed.
1. These trials should be explanatory because the first goal should be to compare the injection of an anesthetic, steroid, or both with placebo injection. 2. Pending proven effectiveness of injection therapy, there is less need for comparing different medications with each other. 3. Future trials should take into account important criteria for methodologic quality such as baseline comparability of groups, concealment of randomization, intention-to-treat analysis, the presentation of frequencies of the most important outcomes, and adequate sample size. 4. The clinically relevant issue of the duration of the effect on pain should receive more attention. Contrary to most trials published in this field, the focus should be on long-term pain relief instead of short-term effects.
Key Points
• This review included 21 randomized trials on injection therapy.
• Only 11 trials compared injection therapy with placebo injections.
• There is insufficient evidence on the effectiveness of facet joint, epidural, and local injection therapy.
• Statistically significant results are lacking, and well-designed trials are scarce.
